AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21263014
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product of C1 esterase inhibitor concentrate
Trial: 17454518
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose = 4.3 mg/day, SD = 1.2)
Trial: 17454518
Drug: Quetiapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (mean dose = 300 mg/day, SD = 66.7)
Trial: 9697878
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with Cyclosporin A (CsA)
Trial: 9697878
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without Cyclosporin A (CsA)
Trial: 2515160
Drug: New liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New liquid formulation of Isocillin syrup
Trial: 2515160
Drug: New liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New liquid formulation of Isocillin syrup plus ethanol
Trial: 2515160
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available penicillin V syrup containing ethanol as solubilizer
Trial: 2515160
Drug: Isocillin film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocillin film tablets
Trial: 27899747
Drug: Aspirin (n=1925)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (n=1925)
Trial: 26402868
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT) delivered in groups of 8 patients and 2 therapists or 4 patients and 1 therapist
Trial: 19178132
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 150 mg twice daily on days 1-3 and once daily on day 4
Trial: 19178132
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg once daily on days 1-4
Trial: 19178132
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments together on days 1-4
Trial: 19178132
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and Dabigatran etexilate (combination treatment)
Trial: 9526179
Drug: Imipramine 50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 50-100 mg/day
Trial: 7786835
Drug: Aldosterone antagonist
RxNorm normalized name: Aldosterone antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone antagonist (spironolactone)
Trial: 7786835
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ACE inhibitor only)
Trial: 21806314
Drug: Alogliptin 6.25
RxNorm normalized name: alogliptin 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 6.25 mg once daily
Trial: 21806314
Drug: Alogliptin 12.5
RxNorm normalized name: alogliptin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5 mg once daily
Trial: 21806314
Drug: Alogliptin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 50 mg once daily
Trial: 30928954
Drug: Voglibose 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose 0.2 mg three times daily
Trial: 2887328
Drug: Hydroxyzine, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine, 25 mg
Trial: 19558008
Drug: Epinastine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinastine, 20 mg
Trial: 11206237
Drug: Fexofenadine, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine, 120 mg
Trial: 10511064
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg R,R‐enantiomer
Trial: 6165336
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for prophylaxis
Trial: 6165336
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics for prophylaxis
Trial: 25017013
Drug: Face mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face mask treatment started after the completion of the Alt‐RAMEC procedure (Group I)
Trial: 25017013
Drug: Face mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face mask treatment started simultaneously with the Alt‐RAMEC procedure (Group II)
Trial: 24952858
Drug: EDTA chelation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA chelation + high-dose vitamins
Trial: 24952858
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion + active vitamins
Trial: 24952858
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion + placebo vitamins
Trial: 24952858
Drug: Double active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double active treatment (EDTA + high-dose vitamins) vs double placebo
Trial: 24952858
Drug: Double active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double active treatment (EDTA + high-dose vitamins) vs double placebo in patients with diabetes
Trial: 23072086
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy (mild-hypothermia + acupuncture)
Trial: 19424699
Drug: Fixed injection
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed injection parameters (Group 1)
Trial: 17329192
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus vinorelbine (1200/30 mg/m2, days 1 and 8)
Trial: 17329192
Drug: Vinorelbine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (30 mg/m2, days 1 and 8)
Trial: 11260417
Drug: Bicarbonate/Lactate (B/L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate/Lactate (B/L) solution
Trial: 11260417
Drug: Control (C)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (C) solution
Trial: 9482763
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg of zinc as zinc sulfate, 4 mL beverage daily for an average of 6.9 months)
Trial: 8015632
Drug: L-dopa/bensearazid-s.r. preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa/bensearazid-s.r. preparation (ASTA H995) 125 mg
Trial: 8015632
Drug: L-dopa/bensearazid-s.r. preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa/bensearazid-s.r. preparation (ASTA H995) 250 mg
Trial: 8015632
Drug: L-dopa/bensearazid-s.r. preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa/bensearazid-s.r. preparation (ASTA H995) 275 mg
Trial: 8015632
Drug: L-dopa/bensearazid-s.r. preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa/bensearazid-s.r. preparation
Trial: 8015632
Drug: L-dopa standard
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa standard preparation
Trial: 25504466
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch (RTP) + Cognitive Stimulation (CS)
Trial: 25504466
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch (RTP)
Trial: 20002476
Drug: Pioglitazone (force
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (force titrated to 45 mg/day)
Trial: 15051755
Drug: Standard radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiation therapy (60 Gy in 30 fractions over 6 weeks)
Trial: 15051755
Drug: Shorter course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter course of radiation therapy (40 Gy in 15 fractions over 3 weeks)
Trial: 26623405
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone (Group D)
Trial: 28980055
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg tranexamic acid (Group T)
Trial: 28980055
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone and 10 mg/kg tranexamic acid (Group DT)
Trial: 27080916
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg daily for 21 days after SWL
Trial: 27080916
Drug: Silodosin 8
RxNorm normalized name: silodosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 8 mg daily for 21 days after SWL
Trial: 27080916
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 21 days after SWL
Trial: 16175942
Drug: Perindopril 8
RxNorm normalized name: perindopril 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 8 mg/day + Irbesartan 300 mg/day
Trial: 1508840
Drug: Zopiclone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone (7.5 mg) + Lorazepam (1 mg)
Trial: 6939009
Drug: l-amphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-amphetamine
Trial: 29957370
Drug: Antidepressants (ADs)
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressants (ADs)
Trial: 27565921
Drug: E300 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E300 (300 mg erlotinib)
Trial: 27565921
Drug: E150 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E150 (150 mg erlotinib)
Trial: 24635528
Drug: Ketamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine and magnesium (Gr K + Mg)
Trial: 15482081
Drug: Phoenix Academy
RxNorm normalized name: Phoenix dactylifera pollen
DrugBank: Phoenix dactylifera pollen (DB10950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phoenix Academy treatment
Trial: 12575390
Drug: Qihuang oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qihuang oral liquid (QHOL)
Trial: 8171952
Drug: Morphine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.15 mg.kg‐1 intravenously)
Trial: 3048224
Drug: Arecoline hydrobromide
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline hydrobromide at 1 mg/h
Trial: 3048224
Drug: Arecoline hydrobromide
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline hydrobromide at 2 mg/h
Trial: 3048224
Drug: Arecoline hydrobromide
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline hydrobromide at 4 mg/h
Trial: 27984918
Drug: Baclofen treatment
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen treatment for AUD
Trial: 19614894
Drug: Sunscreen applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen applied at 2 mg/cm²
Trial: 19614894
Drug: Sunscreen applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen applied at 1.5 mg/cm²
Trial: 19614894
Drug: Sunscreen applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen applied at 1.0 mg/cm²
Trial: 19614894
Drug: Sunscreen applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen applied at 0.5 mg/cm²
Trial: 17885859
Drug: Ciclesonide 80
RxNorm normalized name: CICLESONIDE 80MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 80 micro g
Trial: 17885859
Drug: Ciclesonide 160
RxNorm normalized name: CICLESONIDE 160MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 160 micro g
Trial: 17885859
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 88 micro g
Trial: 15233397
Drug: Microencapsulated fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microencapsulated fish oil (FO) 1.3 g/d long-chain n-3 FA (n-3 LCPUFA)
Trial: 11239740
Drug: Tramadol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (50 mg) with positive expectancy
Trial: 11239740
Drug: Tramadol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (50 mg) with neutral expectancy
Trial: 16091239
Drug: Combination antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antiretroviral therapy (CART)
Trial: 11606959
Drug: Braun Oral‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral‐B 3D Plaque Remover (electric)
Trial: 11606959
Drug: Oral‐B Advantage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B Advantage Control Grip (manual)
Trial: 7925882
Drug: Topical budesonide
RxNorm normalized name: budesonide Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical budesonide (100 micrograms)
Trial: 7925882
Drug: Histamine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine (40 micrograms.ml‐1)
Trial: 2681438
Drug: Induction followed
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction followed by maintenance therapy
Trial: 31959014
Drug: 1500-mg sodium
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500-mg sodium meals
Trial: 31959014
Drug: 3000-mg sodium
RxNorm normalized name: glycerin 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000-mg sodium meals
Trial: 8787428
Drug: Warfarin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (oral anticoagulation)
Trial: 6383839
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg p.o. q 6 hr X 4) and fluphenazine (2.5 mg p.o. q 6 hr X 4)
Trial: 6383839
Drug: Metoclopramide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (20 mg q 6 hr X 4)
Trial: 30740895
Drug: ASP3662 (11β-Hydroxysteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP3662 (11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor)
Trial: 29068578
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (5‐6 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h)
Trial: 29068578
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (5‐6 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h) + 6% desflurane inhalation for 15 min before and after cross-clamping
Trial: 29068578
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (2‐3 mg/kg/h) + fentanyl infusion (3‐5 mcg/kg/h) + continuous 6% desflurane inhalation
Trial: 10709152
Drug: Zanamivir (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir (3.6 to 16 mg) intranasally two or six times daily for 4 to 5 days
Trial: 10709152
Drug: Zanamivir as
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanamivir as an intranasal spray (3.4 mg/nostril), inhaled powder (10 mg), or combination of intranasal and inhaled formulations twice daily for 5 days
Trial: 8930457
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg methylprednisolone administered preoperatively
Trial: 8930457
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group receiving 500 mg methylprednisolone as intraoperative bolus
Trial: 4044467
Drug: latamoxef 6
RxNorm normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: latamoxef 6 g/day for six days
Trial: 4044467
Drug: latamoxef 12
RxNorm normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: latamoxef 12 g/day for four days
Trial: 4044467
Drug: cefotaxime 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefotaxime 12 g/day for seven days
Trial: 4044467
Drug: cefoperazone 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefoperazone 6 g/day
Trial: 30246667
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg oral ketamine, thrice weekly for 21 days
Trial: 27191385
Drug: Single-hormone closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-hormone closed-loop system with simplified meal bolus strategy
Trial: 21796050
Drug: Combination exercise
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination exercise (Aerobic plus Resistance, AR)
Trial: 17667567
Drug: Sugammadex (2.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (2.0, 4.0, 8.0, 12.0, or 16.0 mg/kg)
Trial: 10951430
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg anhydrous theophylline immediate-release (IR) capsules
Trial: 7717633
Drug: Cochlear implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implant surgery
Trial: 2007445
Drug: Ampicillin during
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin during delivery (500 mg i.v./6 h)
Trial: 6261926
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and smoked delta-9-tetrahydrocannabinol (THC)
Trial: 25886265
Drug: Positive Memory
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Positive Memory Training plus Treatment as Usual
Trial: 23370525
Drug: Salsalate (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate (up to 4 g/day)
Trial: 21266141
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (EANT) - no treatment
Trial: 15472657
Drug: Miconazole chewing
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole chewing gum 20 mg/piece (3.6 mg released), administered 4 times daily
Trial: 15472657
Drug: Brentan gel
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brentan gel 2.5 g (50 mg released), administered 4 times daily
Trial: 3592880
Drug: Scotch (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scotch (1 mL of 100-proof per pound of body weight)
Trial: 3592880
Drug: Vodka (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vodka (1 mL of 100-proof per pound of body weight)
Trial: 23719718
Drug: Brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib alaninate 400 mg (Groups A, B, D)
Trial: 23719718
Drug: Brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib alaninate 200 mg (Group C)
Trial: 20946656
Drug: Silicon-rich artesian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon-rich artesian aquifer water (SW) (86 mg/L silica)
Trial: 18760000
Drug: Street- or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Street- or shelter-based interventions including education, free condom distribution, syringe and needle prescription programs, chest radiography screening for tuberculosis, directly observed therapy for tuberculosis treatment, improvement of personal clothing and bedding hygiene, widespread use of ivermectin for scabies and body louse infestation.
Trial: 8558641
Drug: Intravesical plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical plus intradermal BCG
Trial: 8558641
Drug: Positive purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive purified protein derivative skin test before treatment
Trial: 1678761
Drug: Triple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dose cefuroxime
Trial: 1678761
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose cefuroxime
Trial: 1678761
Drug: Triple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dose cefuroxime plus metronidazole
Trial: 1678761
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose cefuroxime plus metronidazole
Trial: 25831700
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg)
Trial: 25831700
Drug: Dabigatran (220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (220 mg)
Trial: 20479419
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 3 weeks for four cycles followed by paclitaxel 175 mg/m² every 3 weeks for four cycles (AC->P)